Scalable production of siRNA‐encapsulated extracellular vesicles for the inhibition of KRAS‐mutant cancer using acoustic shock waves
Journal of Extracellular Vesicles · 2024-09 · 13 (9)
DOI: 10.1002/jev2.12508 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Extracellular Vesicles, online erschienen am 26.09.2024. Verfasst von Hyo Kyeong Kim und 13 weiteren Autor:innen. Beteiligte Einrichtung: Exollence Co., Ltd., Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Extracellular Vesicles, RNA, Small Interfering, Proto-Oncogene Proteins p21(ras). Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Korea Drug Development Fund, Korea Technology and Information Promotion Agency for SMEs, National Research Foundation of Korea.
Abstract (Originalsprache)
Extracellular vesicles (EVs) have emerged as a potential delivery vehicle for nucleic‐acid‐based therapeutics, but challenges related to their large‐scale production and cargo‐loading efficiency have limited their therapeutic potential. To address these issues, we developed a novel “shock wave extracellular vesicles engineering technology” (SWEET) as a non‐genetic, scalable manufacturing strategy that uses shock waves (SWs) to encapsulate siRNAs in EVs. Here, we describe the use of the SWEET platform to load large quantities of KRAS G12C ‐targeting siRNA into small bovine‐milk‐derived EVs (sBMEVs), with high efficiency. The siRNA‐loaded sBMEVs effectively silenced oncogenic KRAS G12C expression in cancer cells; they inhibited tumour growth when administered intravenously in a non‐small cell lung cancer xenograft mouse model. Our study demonstrates the potential for the SWEET platform to serve as a novel method that allows large‐scale production of cargo‐loaded EVs for use in a wide range of therapeutic applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Exollence Co., Ltd., Seoul, Republic of Korea.
- Division of Gastroenterology and Hepatology, School of Medicine, Stanford University, Stanford, California, USA.
- Department of Internal Medicine, College of Medicine, Ewha Womans University, Seoul, Republic of Korea.
ORCID-Profile: Hyo Kyeong Kim
Förderung
- Korea Drug Development Fund
- Korea Technology and Information Promotion Agency for SMEs
- National Research Foundation of Korea
- Korean Ministry of Health and Welfare
Zitieren
APA
Kim, H. K., Choi, Y., Kim, K. H., Byun, Y., Kim, T. H., Kim, J. H., An, S. H., Bae, D., Choi, M. K., Lee, M., Kang, G., Chung, J., Kim, S. H., & Kwon, K. (2024). Scalable production of siRNA‐encapsulated extracellular vesicles for the inhibition of KRAS‐mutant cancer using acoustic shock waves. Journal of Extracellular Vesicles, 13(9). https://doi.org/10.1002/jev2.12508
Vancouver
Kim HK, Choi Y, Kim KH, Byun Y, Kim TH, Kim JH, et al. Scalable production of siRNA‐encapsulated extracellular vesicles for the inhibition of KRAS‐mutant cancer using acoustic shock waves. Journal of Extracellular Vesicles. 2024;13(9). doi:10.1002/jev2.12508
BibTeX
@article{Kim2024,
author = {Kim, Hyo Kyeong and Choi, Yujeong and Kim, Kyoung Hwa and Byun, Yeongju and Kim, Tae Hee and Kim, Jae Hwan and An, Shung Hyun and Bae, DaeHo and Choi, Myeong Kwan and Lee, Minyoung and Kang, Gwansuk and Chung, Jihwa and Kim, Seok-Hyun and Kwon, Kihwan},
title = {Scalable production of siRNA‐encapsulated extracellular vesicles for the inhibition of KRAS‐mutant cancer using acoustic shock waves},
journal = {Journal of Extracellular Vesicles},
year = {2024},
volume = {13},
number = {9},
doi = {10.1002/jev2.12508}
}
EUVIMED